Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
Objectives To examine the accessibility and quality of drug company payment data in Europe.Design Comparative policy review of payment data in countries with different regulatory approaches to disclosure.Setting 37 European countries.Participants European Federation of Pharmaceutical Industries and...
Saved in:
| Main Authors: | Piotr Ozieranski, Shai Mulinari, Luc Martinon, Pierre-Alain Jachiet |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/12/e053138.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)
by: Piotr Ozieranski, et al.
Published: (2020-09-01) -
Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016
by: Marlene Stoll, et al.
Published: (2020-09-01) -
The impact of using electronic payment methods on transparency and disclosure: Case study Jordanian companies
by: Aridah MAMOUN WALID, et al.
Published: (2020-06-01) -
Pillar Two disclosures in annual reports of European listed companies
by: Pieter Dekker, et al.
Published: (2024-11-01) -
The Determinants of Environmental Disclosure in Companies in Indonesia
by: Dina Maulia, et al.
Published: (2020-09-01)